Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 single ascending dose AMT-162 in adults with SOD1 ALS (EPISOD1 rollover)
2024-517244-57-00Phase 2Authorised
- Sponsor
- uniQure
- Start
- Mar 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Gene Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ABP 102 in amyotrophic lateral sclerosis (ALS), sponsored by uniQure. Primary endpoints: Incidence of treatment-emergent adverse events (TEAEs), Mean change from baseline in clinical safety laboratory tests and 2 more. Planned start Mar 2025; status: authorised.
02
Drugs
ABP 102
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-517244-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517244-57-00.